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Abstract
IMPORTANCE Thyroid hormones have been shown to affect several important pathways in cancer
development, including colorectal cancer (CRC). Clinical studies examining the association between
thyroid disorders and colorectal cancer have conflicting results and have predominantly involved
white populations.
OBJECTIVE To determine if a diagnosis of hyperthyroidism or hypothyroidism is associated with the
risk of developing colorectal cancer in an East Asian population.
DESIGN, SETTING, ANDPARTICIPANTS This nationwide population-based case-control study was
conducted fromApril 27, 2018, to November 8, 2018, using the Taiwanese National Health Insurance
Research Database. Participants were adults (n = 139 426) either with a new diagnosis (between
2008 and 2013) of primary colorectal cancer without a history of cancer, or without cancer. Cases
and controls were matched 1:1 by age, sex, and index date. Diagnosis of hyperthyroidism or
hypothyroidism prior to the diagnosis of colorectal cancer (or the same index date in controls) was
then determined.
MAINOUTCOMESANDMEASURES Risk differences in developing colorectal cancer among
patients with a medical history of hyperthyroidism or hypothyroidism.
RESULTS A total of 139 426 patients were included in the study, and 69 713 individuals made up
each case and control group, which were both predominantly male (39 872 [57.2%]). Themean (SD)
age for those with CRCwas 65.8 (13.7) years and for those without CRCwas 66.0 (13.6) years. Both
hyperthyroidism (adjusted odds ratio [aOR], 0.77; 95% CI, 0.69-0.86; P < .001) and hypothyroidism
(aOR, 0.78; 95%CI, 0.65-0.94; P = .008) were associatedwith a decreased risk of being diagnosed
with colorectal cancer. An inverse association of rectal cancer was found among patients aged 50
years or older with a history of hypothyroidism despite treatment (aOR, 0.54; 95% CI, 0.39-0.74;
P < .001). A history of hyperthyroidism in all age groups was associated with a lower risk of colon
cancer (aOR, 0.74; 95% CI, 0.64-0.85; P < .001), with a stronger association seen among those
younger than 50 years (aOR, 0.55; 95% CI, 0.36-0.85; P = .007).
CONCLUSIONS ANDRELEVANCE In this study, hypothyroidism appeared to be associated with a
lower risk of rectal cancer, whereas hyperthyroidism appeared to be associated with a lower risk of
colon cancer. Because of this, biochemical in vivo research and epidemiologic studies appear to be
needed to further clarify the nature of these associations.
JAMA Network Open. 2019;2(5):e193755. doi:10.1001/jamanetworkopen.2019.3755
Key Points
Question Are thyroid disorders
associated with colorectal cancer risk in
an East Asian population?
Findings In this case-control study that
included 139 426 adults in Taiwan with
or without a diagnosis of primary
colorectal cancer, both hyperthyroidism
and hypothyroidism appeared to be
associated with a statistically
significantly decreased risk of colorectal
cancer diagnosis.
Meaning Given these findings, it
appears that biochemical in vivo
research and epidemiologic studies are
needed to further clarify the nature of
the association found between thyroid
disease and colorectal cancer and may
potentially advance the therapies for
colorectal cancer.
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Introduction
Colorectal cancer (CRC) is an increasingly common disease with far-reaching consequences.1 It is the
third most common cancer worldwide2 and the third leading cause of cancer-associated deaths in
the United States, in which 1 in 22men and 1 in 24 women are expected to develop the disease over
the course of their lifetimes.3 Great efforts have been made to further characterize and understand
the pathogenesis of CRC to develop new,more effective treatments for the disease.4-6 As is the case
with many neoplastic processes, with CRC genetic and molecular alterations appear to be involved,
leading to uncontrolled proliferation of these abnormal cells.4
Hormones have been identified as key factors associated with the development and evolution
of many cancers and are being pursued as potential targets for therapy.7-11 This association may be
most obvious within the realm of sex hormones and gynecologic cancers, but the role of trophic
hormones, including the family of thyroid hormones, has come under greater scrutiny. Thyroid
hormones, their nuclear and cellular surface receptors, and even antithyroid antibodies have been
shown to be associated with several important pathways in cancer development.5,6
Studies in largely iodine-replete, white populations report the prevalence of hypothyroidism to
be between 1% and 2%.12 The prevalence of hyperthyroidism ranges from0.1% to0.5% and is higher
among females thanmales.13 Although numerous epidemiologic studies have detailed the
association between thyroid dysfunction and cancer, to date relatively few studies have looked
specifically at the association with CRC.5,6,14-19
Given that CRC is the fourth leading cause of death in Taiwan20 and that previous studies have
involved predominantly non–East Asian populations, we conducted, to our knowledge, the first
population-based study in Taiwan to elucidate the association between hyperthyroidism,
hypothyroidism, and CRC. For this purpose, we used the Taiwanese National Health Insurance
Research Database (NHIRD), what we believe is one of themost comprehensive health care
databases in the world. The goal of this study was to uncover the association between thyroid
dysfunction and CRC risk in an Asian population.
Methods
This study was approved by the institutional review board of Taichung Veterans General Hospital,
Taichung, Taiwan, which granted a waiver of informed consent because data are deidentified.
Conducted from April 27, 2018, to November 8, 2018, this study followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
We designed a large, nationwide, population-based case-control study in which cases were
defined as patients with a new diagnosis of CRC (diagnosed between January 1, 2008, andDecember
31, 2013) and no history of cancer, as recorded in the NHIRD. Controls, thosewithout a CRC diagnosis,
were randomly selected andmatched 1:1 to the cases by age (by amargin of 1 month) and sex. We
subsequently established the presence or absence of thyroid dysfunction prior to the diagnosis of
CRC in the case group and, using the same index date as thematched case patient, in the
control group.
TaiwaneseNHIRD
In 1995, the Taiwanese government established the National Health Insurance Program to provide
coverage for most of the country’s population.21 The National Health Research Institute then created
the NHIRD, a claims database overseen by the Taiwanese Department of Health. The NHIRD has
multiple subset databases, including the Registry for Catastrophic Illness Patient Database and the
Longitudinal Health Insurance Database. Because CRC is administratively assigned to be a
catastrophic illness, a patient with a CRC diagnosis would apply and be registered within the Registry
for Catastrophic Illness Patient Database. The Longitudinal Health Insurance Database includes 1
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million randomly selected persons who represent the total Taiwanese insured population, which
numbered approximately 23 460000 by the end of 2013.21
Case Selection and Case-ControlMatch
Case patients were identified from the NHIRD as having a new CRC diagnosis between 2008 and
2013. Diagnoses for CRCwere registered using the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes 153 and 154, which were cross-linked to the NHIRD.
We used the presence of these codes, combined with a certificate of catastrophic illness, to identify
the initial pool of 74057 potential patient cases.
We excluded from the case group individuals whose age and sex were not known, those who
were younger than 18 years or older than 120 years, and those whowere deceased.We also excluded
those with a diagnosis of malignant diseases before the CRC diagnosis, considering the possibility of
metastasis to the colon or rectum. On the basis of these criteria, we identified a total of 69 713 cases.
A total of 69 713 policyholders were selected as controls in a 1:1 match with cases; they were
randomly paired for age, sex, and the same index date (themonth and year of CRC diagnosis in the
case group) from the 2013 version (consistent with the study time frame) of the Longitudinal Health
Insurance Database. Similar to our process for the case group, we excluded individuals from the
control groupwhose age and sex were not known, whowere younger than 18 years or older than 120
years, who had a diagnosis of other malignant diseases, and whowere deceased before the
index date.
Hyperthyroidism, Hypothyroidism, andOther Adjustments
To identify patients with a thyroid disorder diagnosis, we searched for ICD-9-CM code 242 for
hyperthyroidism and ICD-9-CM codes 243 and 244 for hypothyroidism. Additional criteria for
inclusion were as follows: same diagnosis in at least 3 outpatient visits or 1 inpatient diagnosis
followed by either another inpatient or outpatient visit with the same diagnosis. Patients with a
diagnosis strictly from a single inpatient visit were excluded. The first diagnosis of a thyroid disorder
must occur before the first CRC diagnosis in the case group or before the index date in the control
group. We distinguished patients with acquired hypothyroidism from those with primary
hypothyroidism by identifying the policyholders who first had a hyperthyroidism diagnosis (ICD-
9-CM code 242) followed by hypothyroidism diagnoses (ICD-9-CM codes 244.0, 244.1, 244.2, and
244.3) (Figure).
We adjusted for a history of radioactive iodine treatment, diabetes, benign colorectal polyps,
obesity, inflammatory bowel disease (IBD), and aspirin use. We also adjusted for age; sex; medication
or surgical treatment for thyroid disease; colonoscopy within the 10 years prior to CRC diagnosis (or
index date); and menopausal hormone therapy, including estrogen-only and estrogen-plus-
progesterone treatments and labeling them as either ever used or never used.
Statistical Analysis
We used the χ2 test to analyze categorical variables, to observe differences in clinical characteristics
between the case and control groups. A conditional logistic regression analysis was applied to
examine the association between thyroid disorders (hyperthyroidism, hypothyroidism, and acquired
hypothyroidism) and the risk of developing CRC (CRC, colon cancer, and rectal cancer), in which we
controlled for possible confounders (listed earlier). The confounders were known or were possible
factors associated with CRC development or diagnosis. In the subgroup analysis, a logistic regression
model was applied to examine the association between hyperthyroidism and hypothyroidism
treatments and the risk of developing CRC, adjusted for sex; age; aspirin use; and history of IBD,
obesity, benign polyps, diabetes, radioactive iodine treatment, hormone therapy, and colonoscopy.
Statistical tests were all 2-sided, with P = .05 indicating the statistical significance level, and reported
using 95% CIs and/or P values. All analyses were run using SAS, version 9.4 (SAS Institute Inc). Data
were analyzed fromMay 3, 2018, to May 17, 2018.
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Results
A total of 139 426 patients were included in the study, and 69 713 individuals made up each of the
case and control groups, which were both predominantly male (39 872 [57.2%]). Themean (SD) age
for thosewith CRCwas 65.8 (13.7) years and for thosewithout CRCwas 66.0 (13.6) years. Significant
differences were found between the case group and control group in the proportion of those who
ever used or never used various menopausal hormone therapy (19.7% vs 19.0%; P = .001), had a
history of diabetes (14 506 [20.8%] vs 11 959 [17.2%]; P < .001), had a history of benign colorectal
polyps (1200 [1.7%] vs 500 [0.7%]; P < .001), had a history of aspirin use (13 430 [19.3%] vs 12 416
[17.8%]; P < .001), and had a colonoscopy in the 10 years prior to CRC diagnosis or the same index
date in the control group (53 970 [77.4%] vs 8282 [11.9%]; P < .001). In the case group, only 37
patients had received radioactive iodine treatment before their CRC diagnosis, whereas 33 in the
control group had the same treatment before the index date. A total of 405 patients (0.6%) with
hypothyroidismwere identified in the control group, and 409 patients (0.6%) were identified in the
case group. With regard to a hyperthyroidism diagnosis, 1243 patients (1.8%) were identified in the
control group, and 1137 (1.6%) were identified in the case group (Table 1).
After adjusting for age; sex; aspirin use; and history of IBD, obesity, benign colorectal polyps,
diabetes, radioactive iodine treatment, menopausal hormone therapy, and colonoscopy in the
previous 10 years, we identified both hyperthyroidism and hypothyroidism as associated with a
decreased risk of being diagnosed with CRC.
In all age groups, hypothyroidismwas associated with a 22% lower risk of CRC (odds ratio [OR],
0.78; 95% CI, 0.65-0.94; P = .008) and a 45% lower risk of rectal cancer (OR, 0.55; 95% CI, 0.40-
0.76; P < .001). Overall, hyperthyroidismwas associatedwith a 23% lower risk of CRC (OR, 0.77; 95%
CI, 0.69-0.86; P < .001) and a 26% lower risk of colon cancer (OR, 0.74; 95% CI, 0.64-0.85;
P < .001). In general, for those who acquired hypothyroidism after hyperthyroidism treatment, no
Figure. FlowDiagram of Participant Selection and Study Design
1 000 000 Randomly selected patients in 2013
69 713 Patients without colorectal cancer
65 643 (94.16%) Without 
a history of
thyroid disorders
4070 (5.84%) Patients with a
history of thyroid disorders
(ICD-9 code:
240-246, A180)
65 876 (94.5%) Patients
without a history
of thyroid disorders
3837 (5.5%) Patients with a
history of thyroid disorders
(ICD-9 code:
240-246, A180)
1:1 matched on age,
sex, and index date
69 713 Patients with colorectal cancer
74 057 Patients with newly diagnosed colorectal cancer
(ICD-9-CM code 153,154) with a certificate of
catastrophic illness between 2008 and 2013930 287 Excluded
Exclusion steps
1. Age or sex unknown
2. Age <18 y
or >120 y
3. Had other cancer
before the index date
4. 5524 Had colorectal cancer
5. Died before index date
4344 Excluded
62 Age or sex unknown
26 Age <18 y
or >120 y
4256 Had other cancer
before the index date
409 With a history of
hypothyroidism (ICD-9 code:
243, 244.8, 244.9)
1137 With a history of
hyperthyroidism
(ICD-9 code: 242)
61 With a history of acquired
hypothyroidism (ICD-9 code:
242 and 244.0, 244.1,
244.2, 244.3)
2230 With other
thyroid disorders
405 With a history of
hypothyroidism (ICD-9 code:
243, 244.8, 244.9)
1243 With a history of
hyperthyroidism
(ICD-9 code: 242)
66 With a history of acquired
hypothyroidism (ICD-9 code:
242 and 244.0, 244.1,
244.2, 244.3)
2356 With other
thyroid disorders
No specific number is available for exclusions after random selection. Following the 5524 excludedwho had colorectal cancer, a 1:1 match was performed for age, sex, and index date.
ICD-9-CM indicates International Classification of Diseases, Ninth Revision, Clinical Modification.
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Table 1. Clinical Characteristics of Study Participants
Variable
No. (%)
P Valuea
Total
(N = 139 426)
Without CRC
(n = 69 713)
With CRC
(n = 69 713)
Age, mean (SD), y 65.9 (13.7) 65.8 (13.7) 66.0 (13.6) NA
Sex NA
Female 59 682 (42.8) 29 841 (42.8) 29 841 (42.8)
Male 79 744 (57.2) 39 872 (57.2) 39 872 (57.2)
Thyroid disorders
No. 131 519 (94.3) 65 643 (94.2) 65 876 (94.5)
.07
With hypothyroidism 814 (0.6) 405 (0.6) 409 (0.6)
With hyperthyroidism 2380 (1.7) 1243 (1.8) 1137 (1.6)
With acquired
hypothyroidism
127 (0.1) 66 (0.1) 61 (0.1)
Others 4586 (3.3) 2356 (3.4) 2230 (3.2)
Age <50 y
No. 16 414 (95.2) 8216 (95.3) 8198 (95.1)
.04
With hypothyroidism 50 (0.3) 25 (0.3) 25 (0.3)
With hyperthyroidism 332 (1.9) 176 (2.0) 156 (1.8)
With acquired
hypothyroidism
16 (0.1) 12 (0.1) 4 (0.0)
Others 434 (2.5) 194 (2.2) 240 (2.8)
Age ≥50 y
No. 115 105 (94.2) 57 427 (94.0) 57 678 (94.4)
.02
With hypothyroidism 764 (0.6) 380 (0.6) 384 (0.6)
With hyperthyroidism 2048 (1.7) 1067 (1.7) 981 (1.6)
With acquired
hypothyroidism
111 (0.1) 54 (0.1) 57 (0.1)
Others 4152 (3.4) 2162 (3.5) 1990 (3.3)
Hashimoto diseaseb
No 139 273 (99.9) 69 624 (99.9) 69 649 (99.9)
.04
Yes 153 (0.1) 89 (0.1) 64 (0.1)
Graves diseasec
No 138 516 (99.3) 69 243 (99.3) 69 273 (99.4)
.32
Yes 910 (0.7) 470 (0.7) 440 (0.6)
History of aspirin use
No 113 580 (81.5) 57 297 (82.2) 56 283 (80.7)
<.001
Yes 25 846 (18.5) 12 416 (17.8) 13 430 (19.3)
History of IBD
No 139 399 (100.0) 69 702 (100.0) 69 697 (100.0)
.34
Yes 27 (0.0) 11 (0.0) 16 (0.0)
History of obesityd
No 139 166 (99.8) 69 597 (99.8) 69 569 (99.8)
.08
Yes 260 (0.2) 116 (0.2) 144 (0.2)
History of benign colorectal
polypse
No 137 726 (98.8) 69 213 (99.3) 68 513 (98.3)
<.001
Yes 1700 (1.2) 500 (0.7) 1200 (1.7)
History of diabetesf
No 112 961 (81.0) 57 754 (82.8) 55 207 (79.2)
<.001
Yes 26 465 (19.0) 11 959 (17.2) 14 506 (20.8)
History of radioactive iodine
treatmentg
No 139 356 (99.9) 69 680 (100.0) 69 676 (99.9)
.63
Yes 70 (0.1) 33 (0.0) 37 (0.1)
(continued)
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statistically significant change was found in risk of developing CRC (OR, 0.80; 95% CI,
0.70-0.82; P = .36).
Stratifying by age group revealed that the aforementioned decrease in CRC risk for patients with
hypothyroidism diagnosis was associated with those aged 50 years or older with a rectal cancer
diagnosis (aOR, 0.54; 95% CI, 0.39-0.74; P < .001); no other subgroup of patients with
hypothyroidism diagnosis reached statistical significance. Hyperthyroidism in patients aged 50 years
or older was associated with a lower risk of CRC (aOR, 0.78; 95% CI, 0.70-0.88; P < .001), but the
inverse association wasmost profound in those younger than 50 years, specifically those with colon
cancer (aOR, 0.55; 95%CI, 0.36-0.85; P = .007). No statistical significancewas achieved concerning
rectal cancer among those with a history of hyperthyroidism. The only subgroup with acquired
hypothyroidism that achieved statistical significance comprised patients younger than 50 years, a
small proportion of whom had colon cancer (aOR, 0.12; 95% CI, 0.02-0.94; P = .04).
In a related analysis of the association between autoimmune thyroid diseases and CRC,
statistical significance was achieved concerning Hashimoto disease (aOR, 0.63; 95% CI, 0.41-0.97;
P = .04) but not Graves disease (aOR, 0.87; 95% CI, 0.72-1.04; P = .12). Like hypothyroidism,
Hashimoto disease in patients aged 50 years or older, when stratified by age, was associated with a
Table 1. Clinical Characteristics of Study Participants (continued)
Variable
No. (%)
P Valuea
Total
(N = 139 426)
Without CRC
(n = 69 713)
With CRC
(n = 69 713)
Medication treatment for
thyroid disorderh
No 136 790 (98.1) 68 367 (98.1) 68 423 (98.1)
.27
Yes 2636 (1.9) 1346 (1.9) 1290 (1.9)
Thyroidectomyi
No 138 538 (99.4) 69 260 (99.4) 69 278 (99.4)
.55
Yes 888 (0.6) 453 (0.6) 435 (0.6)
Menopausal hormone therapyj
No 112 456 (80.7) 55 976 (80.3) 56 480 (81.0)
.001
Estrogen only 12 974 (9.3) 6563 (9.4) 6411 (9.2)
Estrogen plus progesterone 4942 (3.5) 2487 (3.6) 2455 (3.5)
Both 9054 (6.5) 4687 (6.7) 4367 (6.3)
Colonoscopy within 10 y of CRC
diagnosis (or index date)k
No 77 174 (55.4) 61 431 (88.1) 15 743 (22.6)
<.001
Yes 62 252 (44.6) 8282 (11.9) 53 970 (77.4)
Abbreviations: CRC, colorectal cancer; IBD, inflammatory bowel disease; NA, not applicable.
a P values calculated with t test, and χ2 test or Fisher exact test used for all other P values.
b Hashimoto disease: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 245.2; 3
outpatient visits or 1 inpatient hospitalization (excluding thosewith only 1 inpatient diagnosis); first diagnosis date before
index date.
c Graves disease: ICD-9-CM code 242.0; 3 outpatient visits or 1 inpatient hospitalization (excluding those with only 1
inpatient diagnosis); first diagnosis date before index date.
d Obesity: ICD-9-CM code 278.0; 3 outpatient visits or 1 inpatient hospitalization; diagnosed 1 year prior to index date.
e Benign colorectal polyps: ICD-9-CM codes 211.3, 211.4, and 569.0; 3 outpatient visits or 1 inpatient hospitalization;
diagnosed 1 year prior to index date.
f Diabetes: ICD-9-CM codes 250 and A181; 3 outpatient visits or 1 inpatient hospitalization; diagnosed 1 year prior to
index date.
g Radioactive iodine treatment: received at least 1 year prior to index date; excluded those within 1 year.
h Medication treatment for thyroid disorder: used between the diagnosis of thyroid disease and index date.
i Thyroidectomy: received between the diagnosis of thyroid disease and index date.
j Menopausal hormone therapy: received at least 1 year prior to index date; excluded those within 1 year.
k Colonoscopy: had 1 within 10 years prior to index date.
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lower risk of CRC (aOR, 0.60; 95%CI, 0.38-0.95; P = .03), more specifically rectal cancer (aOR, 0.34;
95% CI, 0.16-0.70; P = .004); statistical significance was not reached in the younger subgroup
(Table 2).
In a subgroup analysis adjusting for medication and/or surgical treatment for thyroid disorders,
no statistically significant difference was found between previous treatment for hypothyroidism
(aOR, 0.93; 95% CI, 0.66-1.30; P = .66) and hyperthyroidism (aOR, 1.01; 95% CI, 0.82-1.25; P = .90)
and the risk of CRC. Further stratifying hyperthyroidism treatment also revealed no significant
difference between receiving a thyroidectomy (aOR, 1.40; 95% CI, 0.91-2.16; P = .13) and taking
thyroid disorder medication (aOR, 0.97; 95% CI, 0.79-1.21; P = .82) and CRC risk (Table 3).
Discussion
In this case-control study of 139 426 patients that used insurance claims data of nearly the entire
population of Taiwan, we found that, after adjustment for many known risk factors, both
hyperthyroidism and hypothyroidismwere associated with a decreased risk of being diagnosed with
CRC. When stratifying by age, the inverse association between hypothyroidism and rectal cancer
appearedmost pronounced in the subgroup of patients older than 50 years, whereas the inverse
association between hyperthyroidism and colon cancer was most profound in patients younger than
50 years.
This study adds to the body of literature linking thyroid disease and CRC, which has
accumulated some interesting, and seemingly contradictory at times, clinical results.5,6,19,22-26 One
Table 2. Adjusted Odds Ratio of Colorectal, Colon, or Rectal Cancer AssociatedWith Thyroid Disorders
Variable
Colorectal Cancer Colon Cancer Rectal Cancer
Adjusted ORa (95% CI) P Value Adjusted ORa (95% CI) P Value Adjusted ORa (95% CI) P Value
Overall
Without thyroid disorders 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
With hypothyroidism 0.78 (0.65-0.94) .008 0.92 (0.74-1.16) .49 0.55 (0.40-0.76) <.001
With hyperthyroidism 0.77 (0.69-0.86) <.001 0.74 (0.64-0.85) <.001 0.83 (0.69-1.00) .05
With acquired hypothyroidism 0.80 (0.50-1.28) .36 0.75 (0.43-1.30) .30 0.95 (0.41-2.21) .90
With Hashimoto disease 0.63 (0.41-0.97) .04 0.78 (0.46-1.31) .35 0.42 (0.21-0.86) .02
With Graves disease 0.87 (0.72-1.04) .12 0.80 (0.64-1.01) .06 1.00 (0.75-1.34) .99
Others 0.76 (0.70-0.82) <.001 0.81 (0.74-0.89) <.001 0.66 (0.57-0.76) <.001
Age <50 y
Without thyroid disorders 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
With hypothyroidism 1.50 (0.72-3.11) .28 1.44 (0.61-3.41) .41 1.52 (0.39-5.97) .55
With hyperthyroidism 0.67 (0.48-0.94) .02 0.55 (0.36-0.85) .007 0.92 (0.54-1.55) .75
With acquired hypothyroidism 0.32 (0.06-1.66) .17 0.12 (0.02-0.94) .04 1.58 (0.18-13.5) .68
With Hashimoto disease 0.87 (0.24-3.15) .83 0.38 (0.08-1.79) .22 2.66 (0.51-13.94) .25
With Graves disease 0.90 (0.56-1.44) .65 0.74 (0.40-1.37) .34 1.25 (0.59-2.65) .56
Others 0.92 (0.69-1.23) .57 0.89 (0.61-1.30) .54 1.00 (0.63-1.60) .99
Age ≥50 y
Without thyroid disorders 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
With hypothyroidism 0.76 (0.63-0.91) .004 0.90 (0.72-1.14) .40 0.54 (0.39-0.74) <.001
With hyperthyroidism 0.78 (0.70-0.88) <.001 0.76 (0.66-0.88) <.001 0.82 (0.68-1.01) .06
With acquired hypothyroidism 0.90 (0.55-1.48) .69 0.89 (0.50-1.60) .70 0.92 (0.37-2.30) .86
With Hashimoto disease 0.60 (0.38-0.95) .03 0.82 (0.47-1.43) .49 0.34 (0.16-0.70) .004
With Graves disease 0.87 (0.71-1.05) .14 0.81 (0.63-1.03) .09 0.98 (0.71-1.35) .92
Others 0.75 (0.69-0.81) <.001 0.81 (0.73-0.89) <.001 0.64 (0.55-0.74) <.001
Abbreviations: NA, not applicable; OR, odds ratio.
a Odds ratio was adjusted for sex; age; aspirin use; and history of inflammatory bowel
disease, obesity, benign polyps, diabetes, radioactive iodine treatment, menopausal
hormone therapy, and colonoscopy by logistic regression analysis.
JAMANetworkOpen | Diabetes and Endocrinology Thyroid Disorders and Colorectal Cancer Risk in Adult Patients in Taiwan
JAMA Network Open. 2019;2(5):e193755. doi:10.1001/jamanetworkopen.2019.3755 (Reprinted) May 17, 2019 7/12
Downloaded From: https://jamanetwork.com/ by a University of Arizona Health Sciences Library User  on 09/03/2019
study found that, in general, patients with Graves disease have a higher risk of cancer.24 Another
study seems to clarify this finding, reporting the increased cancer risk in hyperthyroid function to be
associatedwith lung and prostate cancer but notwith colon cancer.26 Boursi et al5 and Rennert et al6
both found a negative association between long-term thyroid hormone replacement with
levothyroxine sodium and CRC risk. However, Rennert et al6 did not control for the preceding
hypothyroidism, and Boursi et al5 found an overall higher risk of CRC among those with thyroid
hormone replacement treatment for less than a year, untreated hypothyroidism, or hyperthyroidism.
Shu et al19 found that, in patients hospitalized for Graves disease, risk of colon cancer was statistically
significantly decreased.We hypothesized that these conflicting findingswere largely associatedwith
the complex interactions of thyroid hormones and their associated receptors with both normal and
neoplastic colorectal tissues.
The biochemical association between thyroid hormones and colorectal cell differentiation,
proliferation, tumorigenesis, and apoptosis is an involved andmultifaceted process. The thyroid
primarily secretes 2 hormones: thyroxine (T4) and triiodothyronine (T3).
27 Their adverse effects are
mediated by nuclear receptors TRα1 and TRβ1 and the plasma membrane integrin αVβ3, which has 2
thyroid hormone–binding sites (S1 and S2).28 Only T3 at physiological concentrations can bind to S1,
triggering the phosphorylation and thus activation of the phosphatidylinositol-3-kinase pathway,
which promotes cell proliferation and inhibits apoptosis.29 Activated by both hormones but primarily
T4, S2 triggers the oncogenic extracellular signal-regulated kinase 1/2, facilitating a similar adverse
effect while stimulating angiogenesis and the expression of fibroblast growth factor 2, components
that are essential for rapid tumorigenesis.30,31
Alterations in thyroid hormone receptor TRβ1 have been associated with colorectal adenomas
and cancer, with data suggesting that TRβ1may play a tumor suppressor–type role in malignancy
progression.4 Conversely, overexpression of thyroid hormone receptor TRα1 appears to be
associated with accelerated tumor appearance and progression.32 Similarly, thyroid hormone
receptor interactor 13 has been shown to promote CRC cell proliferation, migration, and invasion33;
T4 has been shown to promote β-catenin activation and cell proliferation in CRC
34; and thyroid
hormone binding of cell surface receptor αVβ3 has been shown to lead to increased tumor cell
proliferation and angiogenesis.5 TRβ1 can also mediate the activation of the phosphatidylinositol-3-
kinase pathway through interplay with T3 to ultimately promote the expression of transcription
factor hypoxia-inducible factor 1’s α subunit; its genomic targets facilitate hypoxia resistance and
angiogenesis found in metastasizing, rapidly growing tumors.27,35
Table 3. Subgroup Analysis for Treatment-Adjusted OR of Colorectal Cancer AssociatedWith TDs
Variable Adjusted ORa (95% CI) P Value
Participants with hypothyroidism
Without TD medications 1 [Reference] NA
With TD medicationb 0.93 (0.66-1.30) .66
Participants with hyperthyroidism
Without TD medications and thyroidectomy 1 [Reference] NA
With TD medicationsc or thyroidectomyd 1.01 (0.82-1.25) .90
With thyroidectomye 1.40 (0.91-2.16) .13
With TD medication 0.97 (0.79-1.21) .82
Abbreviations: NA, not applicable; OR, odds ratio; TD, thyroid disorder.
a Odds ratio was adjusted for sex; age; aspirin use; and history of inflammatory bowel disease, obesity, benign polyps,
diabetes, radioactive iodine treatment, hormone therapy, and colonoscopy by logistic regression analysis.
b Hypothyroidismmedication: levothyroxine sodium.
c Hyperthyroidismmedications: methimazole, propylthiouracil (did not include radioactive iodine treatment because it
was adjusted separately).
d Partial or total thyroidectomy.
e If the patient received both medication and thyroidectomy, the patient would be classified as a surgical patient in this
subgroup.
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Conversely, T3-activated TRα1 is known to directly modulate the transcription of the β-catenin
gene CTNNB1 (MIM 116806), a proto-oncogene pivotal to the canonical Wnt signaling pathway, which
has homeostatic and oncogenic cellular functions. Aberrant Wnt signaling is causally associated with
colon cancer development.31,34,36
Colorectal cancer stem cells represent a small but important chemotherapy-resistant subgroup
in CRCs that can generate the bulk of the tumor with their ability to divide asymmetrically and
symmetrically.37 Thyroid hormone has also been shown to promote CRC stem cell depletion in CRC.38
A study by Catalano et al39 provides a potential mechanism for the inverse association seen among
patients with hyperthyroidism; in their xenografts and in vitro models, T3-treated CRC stem cells had
substantially reduced self-renewal capabilities; down-modulatedWnt signaling; decreased nuclear
β-catenin buildup; and increased sensitivity to treatment, especially when D3 was knocked down.
Intracellular T3 may have antitumorigenic properties as it induces differentiation among CRC stem
cells. Studies also show that right-sided CRC and left-sided CRC share different molecular and genetic
natures and have different levels of response to chemotherapy-or molecular-targeted- and
immunotherapies as well as epidemiologic perspectives, such as incidence in different age groups
and prognosis.2,40-46
Lin et al31 argued that T4’s role in carcinogenesis must be larger than T3 because of its greater
binding affinity to αVβ3 and naturally higher free-circulating levels. In addition, Lee et al34 provided
evidence that T4’s nongenomic actions through binding with αVβ3 also promoted nuclear β-catenin
accumulation and that T4 in a dose-dependent manner promoted cell viability in CRC cell lines.
Therefore, a potential mechanismmay exist in which low free T4 from primary hypothyroidism could
be protective against CRC by decreased interactions with the integrin.
Strengths and Limitations
Strengths of the current study include the large sample size; the source of data representing nearly
the entire population of Taiwan; the case-control design; and the adjustment for multiple CRC risk
factors, including age; sex; aspirin use; and history of IBD, obesity, benign colorectal polyps, diabetes,
iodine treatment, menopausal hormone therapy, and colonoscopy in the previous 10 years. By using
insurance claims data from the NHIRD, we captured the desired data as completely and accurately as
possible. The case-control nature of the study using stored, computerized data from the period in
question nearly eliminates the potential for recall bias, and the large pool of data fromwhich we
pulled the cases and controls lends strength to the associations we found.
Limitations of the study include the homogeneous nature of the study population; lack of data
on the compliance of thyroid hormone replacement; CRC type and stage; and variants of thyroid
disease, such as subclinical hypothyroidism, thyroid adenoma, and toxic nodular goiter. Thyroid
hormone replacement therapy seems to have protective properties against CRC, depending on the
duration of treatment.5 We were not able to completely gather this information from the data, and
this information could affect the associations we found. In addition, the use of ICD-9-CM codes that
exactlymatched hyperthyroidism and hypothyroidismmay not have capturedmany cases along the
spectrum of thyroid disease (eg, subclinical hypothyroidism, thyroid adenomas, and toxic nodular
goiter), which have been suggested to have implications for cancer risk.22,26 We were not able to
collect data on the type of CRC of the case patients. Colorectal cancer is believed to developmostly
through the adenoma-carcinoma sequence, but also either de novo or from flat adenomas.4 The
pathways and signaling in these varying CRC types may differ considerably and therefore display
different associations with hyperthyroid and hypothyroid states.
Conclusions
In this case-control study, both hyperthyroidism and hypothyroidism appeared to be associated with
a decreased risk of being diagnosed with CRC. To bemore specific, hyperthyroidismwas associated
with a lower risk of colon cancer, and hypothyroidism was associated with a lower risk of rectal
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cancer. We hope these findings contribute to the body of literature on the association between
thyroid disease and CRC and lead to changes in clinical practice for these diseases and potential
advances in therapies for CRC. Our findings suggest that further biochemical in vivo research and
epidemiologic studies are needed to clarify the nature of the association between thyroid disease
and CRC and to apply this finding to clinical practice.
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